VIDEO: Azstarys offers ‘another tool in our toolbox’ for ADHD
Click Here to Manage Email Alerts
Ann Childress, MD, president of the Center for Psychiatry and Behavioral Medicine Inc., discussed ADHD data from a poster presented at the American Psychiatric Nurses Association Annual Conference in a video interview with Healio.
Childress discussed results from the phase 3, controlled classroom clinical trial of once-daily oral capsule Azstarys (serdexmethylphenidate and dexmethylphenidate; Corium). The FDA-approved medication significantly reduced ADHD symptoms in children aged 6 to 12 years, according to the data.
“One of the things that is so interesting about this medication is it combines a prodrug. It’s really the first methylphenidate prodrug combined with an immediate release methylphenidate formulation, so it’s quick out of the blocks to start with onset of efficacy and it lasts throughout the day,” Childress said. “It’s nice to have another tool in our toolbox to treat ADHD.”